Patient | Sex, Age | Diagnosis | I | HLA A | HLA B | HLA Cw | Psoriasis, months | ESR | CRP | BASFI | BASDAI | HAQ | VAS | VASg |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F 55 | PsA | P/A | 2–3 | 44–49 | 5–7 | 0 | 10 | 0.1 | 5.0 | 26.5 | 0.5 | 45 | 55 |
2 | M 54 | PsA | P/A | 2 | 18–27 | 7 | 0 | 15 | 3.2 | 28.6 | 52.0 | 0.5 | 75 | 25 |
3 | M 60 | PsA | P | 1–2 | 44–57 | 6–7 | 24 | 11 | 0.1 | 7.0 | 40.0 | 0.9 | 60 | 30 |
4 | M 53 | PsA | P | 1–2 | 8–35 | 5–7 | 252 | 11 | 0.5 | 0.0 | 0.0 | 0.0 | 0 | 10 |
5 | F 49 | PsA | A | — | — | — | 24 | 7 | 0.1 | 3.5 | 22.0 | 0.5 | 70 | 30 |
6 | M 68 | PsA | P/A | — | — | 4–7 | 4 | 0 | 0.2 | 5.0 | 25.0 | 0.1 | 15 | 20 |
7 | M 42 | PsA | P | 1–24 | 38–57 | 6–7 | 9 | 3 | 0.1 | 10.0 | 37.0 | 0.0 | 40 | 60 |
8 | F 56 | AS | A | 28–29 | 44–27 | 4–16 | 0 | 10 | 0.1 | 27.0 | 57.5 | 0.8 | 50 | 50 |
9 | F 59 | PsA | P/A | 23–24 | 35–55 | — | 348 | 10 | 0.0 | 19.5 | 48.0 | 0.0 | 32 | 32 |
10 | F 33 | PsA | P/A | — | — | — | 252 | 0 | 0.5 | 8.2 | 18.5 | 0.5 | 30 | 65 |
11 | F 49 | uSpA | P/A | 24–25 | 18–35 | 4–7 | 0 | 12 | 0.2 | 31.1 | 51.4 | 0.8 | 55 | 68 |
12 | F 48 | uSpA | P/A | — | 35–51 | 6 | 24 | 21 | 1.1 | 9.0 | 74.0 | 0.2 | 20 | 60 |
13 | M 63 | PsA | P/A | 2 | 39–51 | 7 | 0 | 20 | 3.0 | 9.0 | 68.0 | 0.3 | 40 | 40 |
14 | F 42 | AS | P/A | 1–24 | 27–38 | 4 | 0 | 15 | 5.4 | 51.0 | 54.0 | 0.9 | 40 | 60 |
15 | M 37 | AS | A | 2–28 | 13–27 | 2–6 | 0 | 43 | 54.0 | 18.0 | 22.0 | 0.8 | 20 | 30 |
16 | F 57 | PsA | P/A | 24 | 7–35 | 4–7 | 6 | 0 | 3.5 | 42.0 | 80.0 | 1.3 | 50 | 50 |
17 | F 26 | uSpA | P/A | 2 | 7–55 | 7 | 0 | 35 | 0.7 | 2.0 | 13.5 | 0.3 | 30 | 30 |
18 | M 33 | PsA | P/A | 2–24 | 44–55 | 3–5 | 32 | 11 | 0.0 | 10.0 | 31.1 | 0.5 | 35 | 10 |
19 | M 38 | PsA | A | 11 | 39–52 | — | 24 | 10 | 0.9 | 10.0 | 52.0 | 0.8 | 40 | 25 |
20 | F 33 | uSpA | P/A | — | 65–44 | 8–16 | 0 | 4 | 4.1 | 40.0 | 54.0 | 0.5 | 25 | 30 |
21 | M 26 | AS | A | — | 27 | — | 0 | 16 | 1.9 | 51.5 | 53.5 | 1.3 | 55 | 45 |
22 | F 59 | PsA | P/A | 2–26 | 38–51 | 5–12 | 0 | 88 | 4.5 | 82.0 | 89.0 | 2.4 | 95 | 75 |
23 | F 68 | uSpA | P/A | 1–2 | 15–35 | 2–7 | 0 | 2 | 0.0 | 1.0 | 14.0 | 0.1 | 5 | 5 |
24 | M 38 | PsA | P | — | — | — | 240 | 15 | 0.2 | 28.5 | 66.5 | 1.0 | 10 | 10 |
25 | F 62 | uSpA | P/A | — | — | — | 0 | 10 | 0.1 | 34.0 | 27.0 | 0.9 | 60 | 45 |
26 | M 45 | PsA | P | 2 | 44–57 | 7 | 72 | 55 | 2.0 | 17.5 | 29.5 | 0.8 | 45 | 55 |
27 | M 47 | PsA | P | 2–32 | 39–61 | 4 | 72 | 7 | 0.2 | 0.0 | 5.0 | 0.0 | 0 | 2 |
28 | F 26 | AS | P/A | 2 | 18–27 | — | 2 | 18 | 0.6 | 24.0 | 15.0 | 0.9 | 30 | 25 |
29 | M 40 | uSpA | P/A | 2–68 | 35–51 | 1–14 | 120 | 102 | 26.8 | 14.0 | 36.0 | 0.5 | 40 | 40 |
30 | F 72 | PsA | P | — | 7–18 | 7 | 120 | 4 | 2.0 | 13.7 | 44.8 | 0.3 | 40 | 55 |
31 | F 57 | uSpA | P/A | — | 18–39 | 6–7 | 0 | 25 | 3.0 | 3.0 | 22.0 | 0.6 | 30 | 20 |
32 | F 42 | PsA | P/A | 2–24 | 8–44 | 5–7 | 0 | 13 | 0.1 | 18.0 | 28.0 | 0.3 | 35 | 20 |
33 | M 58 | uSpA | P/A | 11–31 | 35–41 | 4–17 | 12 | 2 | 0.1 | 11.0 | 13.5 | 0.8 | 10 | 20 |
34 | F 47 | uSpA | A | 2–11 | 7–56 | 1–7 | 24 | 7 | 0.3 | 24.0 | 46.0 | 0.9 | 20 | 50 |
35 | F 48 | PsA | P/A | 30–68 | 13–51 | 6 | 0 | 10 | 3.4 | 7.0 | 31.0 | 0.9 | 55 | 30 |
36 | M 19 | PsA | P/A | 3–11 | 14–35 | 4–8 | 5 | 50 | 78.8 | 30.0 | 65.0 | 2.3 | 70 | 65 |
37 | F 51 | PsA | P/A | 3–26 | 18–35 | 4 | 48 | 34 | 4.8 | 25.0 | 52.5 | 1.0 | 50 | 28 |
38 | M 36 | PsA | P/A | 2–24 | 18–63 | 7 | 23 | 9 | 0.3 | 3.0 | 52.0 | 0.4 | 20 | 27 |
39 | F 40 | PsA | P/A | 1–33 | 14–52 | 7–8 | 312 | 33 | 0.1 | 17.0 | 38.0 | 0.4 | 30 | 45 |
40 | M 22 | uSpA | P/A | — | 35 | — | 0 | 32 | 0.1 | 25.0 | 61.5 | 1.4 | 65 | 28 |
I: involvement; P/A: peripheral/axial; ESR: erythrocyte sedimentation rate (mm/h); CRP: C-reactive protein (mg/dl); BASFI: Bath Ankylosing Spondylitis Functional Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; HAQ: Health Assessment Questionnaire; VAS: visual analog scale for pain; VASg: visual analog scale for health; SpA: spondyloarthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis.